AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) has announced positive development in advancing preventive strategies and treatment for SARS-CoV-2 caused by COVID-19 disease.
Evaluating Ampligen combination with interferon alfa-2b in COVID-19 patients
The company has reported that the Roswell Park Comprehensive Cancer Centre’s phase 1/2a trial is fully underway, with first studies already enrolled and treated. The study evaluates AIM’s Ampligen in combination with interferon alpha-2b as a possible early-onset treatment for mild-to-moderate COVID-19 and cancer patients.
AIM is the collaborator of the partially funded clinical study through the National Cancer Institute and AIM grants, with Roswell Park offering institutional support. Most importantly, AIM is offering Ampligen for the study at no cost. Dr. Paerl Kalinski and Dr. Brahm Segal are the co-principal investigators in the Roswell park led the study. The study’s primary objective is to determine the safety of intravenously delivered Ampligen in combination or without interferon alfa-2b in COVID patients. The study also seeks to establish the viral load’s kinetics in nasopharyngeal swabs during treatment after 7, 14, and 30 days respectively, after the study regimen’s commencement.
On the other hand, the AIM team is developing an intranasal prophylaxis strategy for the elderly, front-line workers, and high-risk patients, including patients with co-morbidities like cancer. AIM is also working in an effective COVID-19 Long Haulers therapy. The therapy is for patients who show persistent symptoms even after infections are over.
AIM developing a COVID-19 treatment instead of a vaccine
Thomas Equels, the company’s CEO, said that the company is also focusing its efforts on developing an early-onset treatment for COVID-19 patients. This is despite most major pharmaceutical companies globally focusing mostly on delivering a COVID-19 vaccine. For instance, Moderna (NASDAQ:MRNA) and Pfizer Inc. (NYSE:PFE) recently announced significant and promising results of a potential COVID-19 vaccine. Equels said that they are grateful to Dr. Pawel Kalinski and Dr. Brahm Segal and the Roswell Park team’s tremendous efforts to develop a COVID-19 treatment. The CEO said that they are looking forward to offering additional updates about the critical study’s progress.
